Background and Objective: Patients with diabetes mellitus (DM) who are at multiple atherosclerotic cardiovascular disease (ASCVD) risk factor (RF) targets have >50% lower ASCVD risks. Limited “real world” data exists on how often such targets are reached. We studied multiple RF target attainment for ASCVD prevention and its indicators in a contemporary DM registry.

Methods: We determined in the U.S. Diabetes Collaborative Registry those at target for HbA1c (<7.0% or <8.0% if with ASCVD), LDL-C (<100 or <70 mg/dl if ASCVD), blood pressure (<130/80 and <140/90 mmHg), and nonsmoking status by sex, race, and prior history of ASCVD. Multiple logistic regression examined indicators of target attainment.

Results: In 45,134 persons with DM (mean age 68.7 years, 41% female) the Table shows achievement of RF targets. Age (>65 [odds ratio, OR=2.3] or 55-64 [OR=1.5] vs. <55), male sex (OR=1.3), white race (OR=1.4), moderate/high intensity statin use (OR=1.2), middle or high income (OR’s 1.2 and 1.4), and (inversely) private insurance (OR=0.9), depression (OR=0.8), and multiple DM medications (OR= 0.9) (all p<0.to p<0.001) were independently associated with being at all 4 targets (including BP<130/80 mmHg).

Conclusions: Less than 1 in 6 U.S. adults with DM are achieving comprehensive RF control. Multifactorial interventions will be necessary to optimize the prevention of ASCVD.

graphic
View largeDownload slide
Disclosure

N.D. Wong: Research Support; Self; Amarin Corporation, Amgen Inc.. Speaker's Bureau; Self; Sanofi. Consultant; Self; Pfizer Inc.. Research Support; Self; Pfizer Inc.. Y. Song: None. S.V. Arnold: None. L. Sperling: None. C.P. Cannon: Research Support; Self; Amgen Inc., Arisaph Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Takeda Pharmaceuticals U.S.A., Inc.. Consultant; Self; Alnylam, Amarin Corporation, Amgen Inc., Arisaph Pharmaceuticals, Inc., AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Regeneron Pharmaceuticals, Inc., Sanofi, Eisai Inc., GlaxoSmithKline plc., Kowa Pharmaceuticals America, Inc., Lipimedix, Merck & Co., Inc., Pfizer Inc., Takeda Pharmaceuticals U.S.A., Inc. S. Inzucchi: Other Relationship; Self; Boehringer Ingelheim Pharmaceuticals, Inc., AstraZeneca, Novo Nordisk Inc., Sanofi, Lexicon Pharmaceuticals, Inc.. Consultant; Self; VTV Therapeutics. Other Relationship; Self; Intarcia Therapeutics, Inc.. Consultant; Self; Janssen Pharmaceuticals, Inc., Alere Inc. M. Kosiborod: Advisory Panel; Self; AstraZeneca. Consultant; Self; AstraZeneca, Amgen Inc., Sanofi, Boehringer Ingelheim GmbH, GlaxoSmithKline plc., Glytec Systems, Merck & Co., Inc., Novo Nordisk A/S, Janssen Pharmaceuticals, Inc., ZS Pharma, Inc., Intarcia Therapeutics, Inc., Novartis AG. Research Support; Self; AstraZeneca, Boehringer Ingelheim GmbH.

© 2018 by the American Diabetes Association.
2018
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.